Longbio Pharma — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

A biotech firm developing novel antibody and protein-based therapeutics for cancer and autoimmune conditions.

OncologyImmunology

Integrated antibody discovery and protein engineering platform utilizing hybridoma, phage display, and bispecific antibody technologies.

The large and growing demand for biologic therapies in China provides a substantial market for novel, effective antibody drugs.

High risk of failure in early-stage biologic development and intense competition for funding and partnership deals.

Enters a crowded field of Chinese antibody developers, requiring highly differentiated molecules to stand out against more established players.